Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Ono Pharmaceuticals

This page shows the latest Ono Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Ono faces steep price cut for Opdivo in Japan

Ono faces steep price cut for Opdivo in Japan

Japan has followed through on plans for an out-of-cycle price cut for Ono Pharmaceuticals' cancer drug Opdivo, lowering it by 50%. ... Ono has said it is considering filing an objection to the decision, on the grounds that the move will disrupt its

Latest news

  • Immunotherapy and future directions in oncology Immunotherapy and future directions in oncology

    To date, three immune checkpoint inhibitors reached the market: ipilimumab (Yervoy, Bristol-Myers Squibb), nivolumab (Opdivo, Bristol-Myers Squibb and Ono Pharmaceuticals), and pembrolizumab (Keytruda, Merck &Co.) - all three marketed for

  • Ipragliflozin beats diabetes rivals to Japanese approval Ipragliflozin beats diabetes rivals to Japanese approval

    The Japanese regulatory authorities have cleared ipragliflozin under the Suglat trade name for the treatment of type 2 diabetes, beating rivals Ono Pharmaceuticals/AstraZeneca and Johnson &Johnson who have filed their

  • Promising new agents for multiple myeloma Promising new agents for multiple myeloma

    Chemotherapy: Proteasome inhibitors. There are currently two approved proteasome inhibitors - bortezomib (Velcade, Millennium Pharmaceuticals) and carfilzomib (Kyprolis, Ono Pharmaceutical) - both of which are administered intravenously. ... A third

  • Salix licenses Progenics' Relistor

    Salix Pharmaceuticals has licensed worldwide rights excluding Japan to the opioid-induced constipation drug Relistor from Progenics Pharmaceuticals. ... Salix will fund all development, registration and commercialisation activities for Relistor, except

  • R&D news in brief

    The drug, which was licensed from Japan's Ono Pharmaceuticals, is in a race to market with its rival CCR inhibitor, Pfizer's Maraviroc.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    In the second immuno-therapy deal to make the top 20 this month ONO Pharmaceuticals paid $12.5m upfront for the rights to develop Celyad's phase I product, allogeneic ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links